|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||40.38 - 40.74|
|52 Week Range||37.20 - 44.54|
|PE Ratio (TTM)||40.34|
|Dividend & Yield||1.99 (4.97%)|
|1y Target Est||N/A|
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.